To view more news and media here in our Newsroom

Click Here

Georgetown Announces Phase II Clinical Trial of Nilotinib for Parkinson’s Disease

WASHINGTON  – Georgetown University Medical Center (GUMC) today announces the launch of a phase II clinical trial to study the safety of the cancer drug nilotinib and its effects on clinical outcomes and biomarkers in people with Parkinson’s disease.  GUMC is recruiting volunteers for the study in collaboration with its clinical partner, MedStar Georgetown University Hospital. The clinical trial is a phase II, randomized, double-blind, placebo-controlled study designed to evaluate the safety and tolerability of low doses of nilotinib, the efficacy on disease biomarkers, and clinical outcomes in people with mid-stage Parkinson’s disease. Fernando Pagan, MD, medical director of the GUMC…

Read More

Maryland Woman Benefits when Two Emerging Areas of Science Aimed at Beating Cancer Come Together

Precision Medicine and Immunotherapy: Tomorrow’s Cancer Treatments Today at MedStar Georgetown (Washington, D.C.)  – A Maryland woman is benefitting from the intersection of two promising fields of science: precision medicine to genetically profile cancer and immunotherapy to unleash the immune system to fight it. It’s a case her doctors are calling “remarkable.” Diane Lucey, 49 of Leonardtown, Maryland was living in Georgia in 2014 when she noticed a small bump in her mouth.  The two centimeter tumor was determined to be a rare type of cancer called neuroendocrine carcinoma. She had it surgically removed, received six weeks of radiation and thought…

Read More

Healthy Heart Advice for Women

 "Goldilocks" Exercise and SleepExercise and good rest are healthy habits, right?  What is the right amount for optimal cardiovascular health? For exercise, brisk walking is good enough - 30 to 60 minutes on most days of the week does the trick!  Women who exercise moderately and regularly experience fewer than half as many heart attacks as those who don’t. And, research in healthy women shows that the optimal sleep duration is seven hours.  Less than seven hours is associated with increased heart risk.  Now here’s the interesting part:  you can get too much of a “good thing.”  Exercise and sleep…

Read More

Georgetown Clinical Trial Testing Nilotinib in Alzheimer’s Disease Begins

WASHINGTON (January 24, 2017) – A clinical trial to examine the effect of nilotinib on clinical outcomes and biomarkers in people with mild to moderate Alzheimer’s disease has opened at Georgetown University Medical Center (GUMC).The clinical trial is a phase II, randomized, double blinded, placebo-controlled study to evaluate the impact of low doses of the cancer drug nilotinib (Tasigna®). GUMC is conducting the study with its clinical partner, MedStar Georgetown University Hospital.The rationale for using nilotinib is based on laboratory and clinical research conducted by the Georgetown Translational Neurotherapeutics Program (TNP). Nilotinib appears to aid in the clearance of accumulated…

Read More

Top News
Georgetown Announces Phase II Clinical Trial of Nilotinib for Parkinson’s Disease
News
Georgetown Announces Phase II Clinical Trial of Nilotinib for…
Close
What can we
Help you Find?

Begin your search for a physician, service or location.

Find a Doctor

Start looking for the right physician to meet your health needs.

Find a Doctor

Call Us Today

Schedule an appointment or get more information about our services.

855-MED-0364

Contact Us

For access to unsurpassed health care treatment, contact us now.

Contact Us